Etrank: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial.

Abstract:

:ETRANK is a statistical software which uses nonparametric (randomization) technique to analyze incomplete repeated measures data, where the pattern of withdrawal is treatment related. This stand alone program is written in C, presently runs in MS-DOS, and a Windows version is in development. The program has been developed based on methods developed by Entsuah (1990). These methods were presented at Statistics and Statistical Graphics Section of the 1991 SAS Users Group International Conference (SUGI-16). They were also presented to the Biometric Division of US Food and Drug Administration (FDA). ETRANK is now being used by CNS group of Wyeth-Ayerst Research as part of their NDA submission. This paper discusses ETRANK, and compares it with SAS PROC MIXED, and GEE. These methods are applied to Wyeth-Ayerst antidepressant Effexor-ER (extended release) data.

journal_name

J Biopharm Stat

authors

Entsuah R

doi

10.1080/10543409608835156

subject

Has Abstract

pub_date

1996-11-01 00:00:00

pages

457-75

issue

4

eissn

1054-3406

issn

1520-5711

journal_volume

6

pub_type

杂志文章,评审
  • Exact inference for complex clustered data using within-cluster resampling.

    abstract::This paper introduces exact permutation methods for use when there are independent clusters of data with arbitrary within-cluster correlation. To eliminate the problem of clustering, we randomly select a data point from each cluster and for this now independent data, and calculate our test statistic and the associated...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543401003618884

    authors: Follmann D,Fay M

    更新日期:2010-07-01 00:00:00

  • Dual composite reference standards (dCRS) in molecular diagnostic research: A new approach to reduce bias in the presence of Imperfect reference.

    abstract::A main challenge in molecular diagnostic research is to accurately evaluate the performance of a new nucleic acid amplification test when the reference standard is imperfect. Several approaches, such as discrepant analysis, composite reference standard (CRS) method, or latent class analysis (LCA), are commonly applied...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2018.1428613

    authors: Tang S,Hemyari P,Canchola JA,Duncan J

    更新日期:2018-01-01 00:00:00

  • Power and sample size for the S:T repeated measures design combined with a linear mixed-effects model allowing for missing data.

    abstract::Tango (Biostatistics 2016) proposed a new repeated measures design called the S:T repeated measures design, combined with generalized linear mixed-effects models and sample size calculations for a test of the average treatment effect that depend not only on the number of subjects but on the number of repeated measures...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1293083

    authors: Tango T

    更新日期:2017-01-01 00:00:00

  • Mixed-effects varying-coefficient model with skewed distribution coupled with cause-specific varying-coefficient hazard model with random-effects for longitudinal-competing risks data analysis.

    abstract::It is well known that there is strong relationship between HIV viral load and CD4 cell counts in AIDS studies. However, the relationship between them changes during the course of treatment and may vary among individuals. During treatments, some individuals may experience terminal events such as death. Because the term...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2015.1052493

    authors: Lu T,Wang M,Liu G,Dong GH,Qian F

    更新日期:2016-01-01 00:00:00

  • Subgroup analyses in randomized clinical trials: statistical and regulatory issues.

    abstract::Recently, two CPMP Points to Consider, one on adjustment for baseline covariates and the other on multiplicity issues in clinical trials, have included recommendations on the use of subgroup analysis for regulatory purposes. However, despite their regular use and regulatory attention, the validity and nature of subgro...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-200067988

    authors: Grouin JM,Coste M,Lewis J

    更新日期:2005-01-01 00:00:00

  • Analysis of recurrent hypoglycemic events.

    abstract::Hypoglycemia is a major safety concern for diabetic patients. Hypoglycemic events can be modeled based on time to recurrent events or count data. In this article, we evaluated a gamma frailty model with variance estimated by the inverse of observed Fisher information matrix, a gamma frailty model with the sandwich var...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2020.1765370

    authors: Ma C,Qu Y,Fu H

    更新日期:2020-05-18 00:00:00

  • On sample size determination in multi-armed confirmatory adaptive designs.

    abstract::An important application of confirmatory adaptive designs is the data-driven selection of treatment arms in multi-armed trials. A general methodology for adaptive designs is based on the combination testing principle. Using this principle, selection of treatment arms in multi-armed designs, recalculation of sample siz...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2011.551336

    authors: Wassmer G

    更新日期:2011-07-01 00:00:00

  • Sample size determination for Bayesian analysis of small n sequential, multiple assignment, randomized trials (snSMARTs) with three agents.

    abstract::The small n, Sequential, Multiple Assignment, Randomized Trial (snSMART) is a two-stage clinical trial design for rare diseases motivated by the comparison of three active treatments for isolated skin vasculitis in the ongoing clinical trial ARAMIS (a randomized multicenter study for isolated skin vasculitis, NCT09239...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2020.1815032

    authors: Wei B,Braun TM,Tamura RN,Kidwell K

    更新日期:2020-09-06 00:00:00

  • Stochastic optimization of adaptive enrichment designs for two subpopulations.

    abstract::An adaptive enrichment design is a randomized trial that allows enrollment criteria to be modified at interim analyses, based on a preset decision rule. When there is prior uncertainty regarding treatment effect heterogeneity, these trial designs can provide improved power for detecting treatment effects in subpopulat...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2018.1489401

    authors: Fisher A,Rosenblum M,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期:2018-01-01 00:00:00

  • Power approximation for the van Elteren test based on location-scale family of distributions.

    abstract::The van Elteren test, as a type of stratified Wilcoxon-Mann-Whitney test for comparing two treatments accounting for stratum effects, has been used to replace the analysis of variance when the normality assumption was seriously violated. The sample size estimation methods for the van Elteren test have been proposed an...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400600762939

    authors: Zhao YD,Qu Y,Rahardja D

    更新日期:2006-01-01 00:00:00

  • Test procedures for disease prevalence with partially validated data.

    abstract::Investigating the prevalence of a disease is an important topic in medical studies. Such investigations are usually based on the classification results of a group of subjects according to whether they have the disease. To classify subjects, screening tests that are inexpensive and nonintrusive to the test subjects are...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.544527

    authors: Tang ML,Qiu SF,Poon WY,Tang NS

    更新日期:2012-01-01 00:00:00

  • Design and sample size for evaluating combinations of drugs of linear and loglinear dose-response curves.

    abstract::The study of drug combinations has become important in drug development due to its potential for efficacy at lower, less toxic doses and the need to move new therapies rapidly into clinical trials. The goal is to identify which combinations are additive, synergistic, or antagonistic. Although there exists statistical ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400902964019

    authors: Fang HB,Tian GL,Li W,Tan M

    更新日期:2009-07-01 00:00:00

  • Determining a minimum clinically important difference between treatments for a patient-reported outcome.

    abstract::Patient-reported outcomes are important for assessing the effectiveness of treatments in many disease areas. For this reason, many new instruments that capture patient-reported outcomes have been developed over the past several decades. With the development of each new instrument, there is the ensuing question of what...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400903315757

    authors: Kirby S,Chuang-Stein C,Morris M

    更新日期:2010-09-01 00:00:00

  • A bootstrap-based test for establishing noninferiority in clinical trials.

    abstract::A randomized, active-control clinical trial setting with the objective of testing noninferiority for a continuous response variable is considered. Noninferiority margin is based on the concept of preserving a certain fraction of the active control effect. Noninferiority is established if the ratio of the lower (upper)...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400600609478

    authors: Chen M,Kianifard F,Dhar SK

    更新日期:2006-05-01 00:00:00

  • Analytical expressions for combining population pharmacokinetic parameters from different studies.

    abstract::We provide a set of formulas that allow the combination of separately performed analyses of population pharmacokinetic (PK) studies, without any further computational effort. More specifically, given the point estimates and uncertainties of two population PK analyses, the formulas provide the point estimates and uncer...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802071360

    authors: Dokoumetzidis A,Aarons L

    更新日期:2008-01-01 00:00:00

  • On sample size estimation and re-estimation adjusting for variability in confirmatory trials.

    abstract::Sample size estimation (SSE) is an important issue in the planning of clinical studies. While larger studies are likely to have sufficient power, it may be unethical to expose more patients than necessary to answer a scientific question. Budget considerations may also cause one to limit the study to an adequate size t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2015.1092031

    authors: Wu PS,Lin M,Chow SC

    更新日期:2016-01-01 00:00:00

  • A predictive Bayesian approach to the design and analysis of bridging studies.

    abstract::Pharmaceutical product development culminates in confirmatory trials whose evidence for the product's efficacy and safety supports regulatory approval for marketing. Regulatory agencies in countries whose patients were not included in the confirmatory trials often require confirmation of efficacy and safety in their p...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2012.701579

    authors: Gould AL,Jin T,Zhang LX,Wang WW

    更新日期:2012-09-01 00:00:00

  • Modeling sustained treatment effects in tumor xenograft experiments.

    abstract::In cancer drug development, demonstrated efficacy in tumor xenograft models is an important step toward bringing a promising compound to human use. A key outcome variable is tumor volume measured over a period of time, while mice are treated with certain treatment regimens. A constrained parametric model has been prop...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.901340

    authors: Fang HB,Deng D,Zhang T,Tan M

    更新日期:2014-01-01 00:00:00

  • Linear structural equation model in analyzing quality-of-life-data from clinical trials.

    abstract::Assessment of quality of life (QOL) in clinical trials becomes a challenging task from the viewpoint of clinical biostatistics. The responses of the items for measuring QOL indices usually vary widely from patient to patient and from time to time. Measurement errors might be present in the responses of the items, and ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/bip-100101202

    authors: Siddiqui O,Ali MW

    更新日期:1999-11-01 00:00:00

  • Some controversial multiple testing problems in regulatory applications.

    abstract::Multiple testing problems in regulatory applications are often more challenging than the problems of handling a set of mathematical symbols representing multiple null hypotheses under testing. In the union-intersection setting, it is important to define a family of null hypotheses relevant to the clinical questions at...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802541693

    authors: Hung HM,Wang SJ

    更新日期:2009-01-01 00:00:00

  • Optimal population designs for PK models with serial sampling.

    abstract::In various pharmaceutical applications, repeated measurements are taken from each subject, and model parameters are estimated from the collected data. Examples include dose response modeling and PK/PD studies with serial blood sampling, among others. The quality of the information in an experiment is reflected in the ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/bip-200040853

    authors: Gagnon R,Leonov S

    更新日期:2005-01-01 00:00:00

  • A likelihood and resampling based approach to dichotomizing a continuous biomarker in medical research.

    abstract::Dichotomizing a continuous biomarker is a common practice in medical research. Various methods exist in the literature for dichotomizing continuous biomarkers. The most widely adopted minimum p-value approach uses a sequence of test statistics for all possible dichotomizations of a continuous biomarker, and it chooses...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2012.756503

    authors: Su M,Fang L,Su Z

    更新日期:2013-05-01 00:00:00

  • Bayesian approach for cure models with a change-point based on covariate threshold: application to breast cancer data.

    abstract::In this study, a Bayesian approach was suggested to estimate a change-point according to a covariate threshold when some patients never experienced the event of interest. Gibbs sampler algorithm with latent binary cure indicators was used to simplify the implementation of Markov chain Monte Carlo method. Then, the acc...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2019.1632877

    authors: Shamsi F,Baghestani AR,Binesh F

    更新日期:2020-03-01 00:00:00

  • Optimal two-stage randomized multinomial designs for Phase II oncology trials.

    abstract::A new two-stage design is proposed that is suitable for early detection of the anticancer activity of experimental therapies in Phase II oncology trials. The endpoints of interest are response rate and early progression rate. The anticancer activity is defined by a positive signal in one endpoint and a non-negative si...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400902802417

    authors: Sun LZ,Chen C,Patel K

    更新日期:2009-01-01 00:00:00

  • Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data.

    abstract::In this paper, a propensity score-integrated composite likelihood (PSCL) approach is developed for cases in which the control arm of a two-arm randomized controlled trial (RCT) (treated vs control) is augmented with patients from real-world data (RWD) containing both clinical outcomes and covariates at the patient-lev...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2020.1730877

    authors: Chen WC,Wang C,Li H,Lu N,Tiwari R,Xu Y,Yue LQ

    更新日期:2020-05-03 00:00:00

  • Designing studies to find early signals of efficacy.

    abstract::We introduce the idea of a design to detect signals of efficacy in early phase clinical trials. Such a design features three possible decisions: to kill the compound; to continue with staged development; or to continue with accelerated development of the compound. We describe how such studies improve the trade-off bet...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2011.570466

    authors: Brown MJ,Chuang-Stein C,Kirby S

    更新日期:2012-01-01 00:00:00

  • Assessment of antitumor activity for tumor xenograft studies using exponential growth models.

    abstract::In preclinical tumor xenograft experiments, the antitumor activity of the tested agents is often assessed by endpoints such as tumor doubling time, tumor growth delay (TGD), and log10 cell kill (LCK). In tumor xenograft literature, the values of these endpoints are presented without any statistical inference, which ig...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.481802

    authors: Wu J

    更新日期:2011-05-01 00:00:00

  • A group sequential approach to crossover trials for average bioequivalence.

    abstract::Group sequential methods to allow the possibility of early termination of a trial due to sufficiently convincing results are a standard in therapeutic clinical trials but have been little considered in bioequivalence trials. We investigate the statistical properties of one group sequential approach to bioequivalence t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409708835171

    authors: Hauck WW,Preston PE,Bois FY

    更新日期:1997-03-01 00:00:00

  • Distribution of odds ratio in 2 × 2 contingency table: adjustment for correlation.

    abstract::The Log-odds ratio for 2 × 2 contingency tables is often approximated by a normal distribution with an approximated variance. Hwang and Biswas (2008) illustrated that the standard expression for the variance should be modified in the presence of correlation. They also provided an adjustment to this variance expression...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.494268

    authors: Biswas A,Hwang JS

    更新日期:2011-01-01 00:00:00

  • Alternative approaches to the analysis of binary and categorical repeated measurements.

    abstract::The purpose of this paper is to describe, illustrate, and compare a number of different approaches to the analysis of repeated binary and categorical data. These approaches include empirical generalized least squares and generalized estimating equations, as well as traditional log-linear modeling methods. It is shown ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543409208835036

    authors: Kenward MG,Jones B

    更新日期:1992-01-01 00:00:00